Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer

Annals of Thoracic Surgery

Volumn 81, Issue 2, 2006, Pages 440-447

  D'Amato, Thomas A ^a   Landreneau, Rodney J ^b   McKenna, Robert J ^b   Santos, Ricardo S ^b   Parker, Ricardo J ^b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; THYMIDINE; TOPOTECAN; VINCA ALKALOID;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURGERY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FATALITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 31044443728     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2005.08.037     Document Type: Article

References (22)

1. American Cancer Society Facts and figures 2005 2005 American Cancer Society Atlanta 13
2. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
3. C.J. Langer, P. Stephenson, A. Thor Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598 J Clin Oncol 22 2004 1180 1187
4. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
5. G.M. Strauss, J. Herndon, M.A. Maddaus Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC) report of Cancer and Leukemia Group B (CALGB) Protocol 9633 J Clin Oncol 22 2004 7019
6. T.L. Winton, R. Livingston, D. Johnson A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC). Intergroup JBR.10 N Engl J Med 352 2005 2289 2297
7. E. Mechetner, A. Kyshtoobayeva, S. Zonis Levels of multidrug resistance (MDR-1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin Cancer Res 4 1998 389 398
8. J.P. Fruehauf, A.G. Bosanquet In vitro determination of drug response a discussion of clinical applications Principles Practices Oncol Updates 7 1993 1 17
9. D. Alberts, S.E. Salmon, G.H.-S. Chen, T.E. Moon, L. Young, E.A. Surwit Pharmacologic studies of anticancer drugs with the human tumor stem cell assay Cancer Chemo Pharmacol 6 1981 253 264
10. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer a meta-analysis using updated data on individual patients from 52 randomized clinical trials BMJ 311 1995 899 909
11. S.M. Keller, S. Adak, H. Wagner A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer N Engl J Med 343 2000 1217 1222
12. G.V. Scagliotti, R. Fossati, V. Torri Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non small-cell lung cancer J Natl Cancer Inst 95 2003 1453 1461
13. J. Douillard, R. Rosell, M. Delena Adjuvant Navelbine International Trialist Association (ANITA) Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts) final results after 70-month median follow-up J Clin Oncol 23 2005 7013
14. P. Selby, R. Buick, I. Tannock A critical appraisal of the human tumor stem cell assay N Engl J Med 308 1983 129 134
15. J. Fruehauf, A. Bosanquet In vitro determination of drug response a discussion of clinical applications PPO Updates 12 1993 1 16
16. D. Kern, L. Weisenthal Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharacologic drug exposures J Natl Cancer Inst 82 1990 582 588
17. V. Loizzi, J.K. Chan, K. Osann, F. Cappuccini, P.J. DiSaia, M.L. Berman Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy Am J Obstet Gynecol 189 2003 1301 1307
18. R. Holloway, R. Mehta, N. Finkler Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol 87 2002 8 16
19. R. Mehta, R. Bomstein, I.-R. Yu Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res Treat 66 2001 225 237
20. R.J. Parker, J.P. Fruehauf, R. Mehta, E. Filka, T. Cloughesy A prospective blinded study of predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma J Neuro-Oncol 66 2004 365 375
21. J. Schiller, D. Harrington, C. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
22. R. Rosell, M. Cobo, D. Isla ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p) J Clin Oncol 23 2005 7002